Opendata, web and dolomites

CAR ART SIGNED

Chimeric Antigen Receptor to generate Alloantigen-specific Regulatory T cells and promote allograft tolerance

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 CAR ART project word cloud

Explore the words cloud of the CAR ART project. It provides you a very rough idea of what is the project "CAR ART" about.

allograft    valbonne    tolerance    transplantation    preclinical    eacute    ambition    translation    limited    humoral    alloantigens    position    return    lab    donor    enhanced    human    performed    morbidity    relies    glaichenhaus    toward    experimental    cellulaire    clinic    kidney    potency    survival    infections    family    immune    alloantigen    specificity    transfer    drugs    treg    immunologists    data    destructive    pharmacologie    expanded    outgoing    cd4foxp3    cancers    culaire    limitation    lack    rejection    grail    global    receptor    hindered    prevention    redirect    clinical    tregs    indicated    car    de    graft    tenured    action    team    models    vancouver    generate    induction    regulatory    pr    treatment    ing    levings    therapy    canada    cellular    chimeric    adoptive    few    strategies    terminal    ex    vivo    france    risk    sufficient    antigen    cells    mol    overcome    alloimmune    fellowship    group    child    potent    trial    life    researcher    institut    successfully    et    applicable    organ    clinically    indefinite    recipient    markedly    immunosuppressive    transplant    supporting   

Project "CAR ART" data sheet

The following table provides information about the project.

Coordinator
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS 

Organization address
address: RUE MICHEL ANGE 3
city: PARIS
postcode: 75794
website: www.cnrs.fr

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Total cost 171˙349 €
 EC max contribution 171˙349 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2016
 Funding Scheme MSCA-IF-GF
 Starting year 2017
 Duration (year-month-day) from 2017-11-01   to  2019-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS FR (PARIS) coordinator 171˙349.00
2    UNIVERSITY OF BRITISH COLUMBIA CA (VANCOUVER) partner 0.00

Map

 Project objective

Organ transplantation is the best life-supporting treatment for terminal organ failure. Graft survival is however limited by rejection, a destructive process resulting from the response of recipient’s immune system against donor specific alloantigens. Prevention of rejection currently relies on immunosuppressive drugs that lack antigen specificity and therefore increase the risk for infections and cancers. Induction of donor-specific tolerance would provide indefinite graft survival without morbidity and therefore represents the Grail of transplant immunologists. Tolerance has been obtained in experimental models with adoptive transfer of ex vivo-expanded CD4FOXP3 regulatory T cells (Treg). Preclinical studies have indicated that the potency and specificity of Treg therapy could be markedly enhanced by the use of Treg specific for donor alloantigens. Translation of this approach in the clinic has been hindered by the lack of clinically applicable strategies to generate sufficient numbers of potent donor-specific Tregs. To overcome this limitation, Pr Levings’ group (Child and Family Research Institute, Vancouver, Canada) has just recently successfully used chimeric antigen receptor (CAR) technology to redirect the specificity of human Treg toward a transplant-relevant antigen. The objective of the 2-year action is to assess the impact of alloantigen-specific CAR Treg on cellular and humoral alloimmune responses and their ability to promote allograft tolerance. The outgoing phase of the global fellowship will be performed in Pr Levings’ lab, and the return phase in Pr Glaichenhaus’ team (Institut de Pharmacologie Moléculaire et Cellulaire, Valbonne, France) where the researcher will get in few years a tenured position. The main ambition of the program is to provide key data for the development of a clinical trial with CAR Tregs in kidney transplantation.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CAR ART" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CAR ART" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

MingleIFT (2020)

Multi-color and single-molecule fluorescence imaging of intraflagellar transport in the phasmid chemosensory cilia of C. Elegans

Read More  

MarshFlux (2020)

The effect of future global climate and land-use change on greenhouse gas fluxes and microbial processes in salt marshes

Read More  

NeoPur (2019)

New treatments and novel diagnostic tests for neonatal seizures based on purinergic signaling.

Read More